The rise of Viagra and its influence on the drug landscape presents a complex question for shareholders. While the first sales statistics were astounding, the patent has expired, leading to a wave of off-brand alternatives that are eroding earnings. Moreover, the market is facing difficulties related to demographic trends and evolving healthcare re